Equipoise for Laminoplasty Versus Fusion for Cervical Spondylotic Myelopathy: Is a Randomized Trial Feasible?
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND AND OBJECTIVES: There is global variation and uncertainty regarding the utilization of laminoplasty in the treatment of patients with degenerative cervical spondylotic myelopathy. We asked whether clinical equipoise can be established among cervical spine surgeon experts for a possible trial comparing laminoplasty with fusion. METHODS: Fifty randomly selected cases from a cervical spondylotic myelopathy trial [NCT-02076113] were presented to 26 cervical spine experts to determine the suitability of randomization to laminoplasty vs fusion surgery. A brief clinical vignette, sagittal T2-weighted MRI, and appropriate axial images were reviewed by the experts. Each expert assessed the randomizability of each case and then stated the choice of approach: laminoplasty, fusion (anterior or posterior), arthroplasty, or no surgery. After 6 months, the same 50 cases were reviewed by all experts. RESULTS: Among 50 cases, 46 (92%) were deemed suitable for randomization by a simple majority at both time points. The response rate of the expert panel members was 100% at both time points. Among 2600 surgeon responses over 2 time points, experts stated their choice of approach as laminoplasty in 40% of instances and selected fusion (anterior or posterior) in 57% of cases. Temporal stability of decision-making was high with mean stability = 0.85 (SD = 0.09), indicating that surgeons generally maintained similar treatment decisions over 6 months. A subset (12 experts) of the expert panel who reviewed these 50 cases over 10 years ago demonstrated a significant increase in the preference for laminoplasty from 18% to 40% ( P < .001). CONCLUSION: Among cervical spine experts, laminoplasty utilization has increased over 10 years. Global cervical spine experts demonstrate equipoise for comparing laminoplasty with fusion. The results suggest that a significant proportion of patients with cervical myelopathy would be eligible for a future trial and the results would be likely to affect global practice.
Source: Neurosurgery Open
Authors: Zoher Ghogawala, Tasneem Z. Rizvi, Madison E. Liesching, Ryan D. Adkins, Michael Y. Wang, Praveen V. Mummaneni, Daniel K. Resnick, James S. Harrop, Fehlings G. Michael, K. Daniel Riew, Todd J. Albert, Robert G. Whitmore, Luis M. Tumialan, Daniel J. Hoh, Asdrubal Falavigna, Alpesh A. Patel, Paul M. Arnold, Vincent C. Traynelis, Wilson Z. Ray, Michael P. Steinmetz, Subu N. Magge, Dean Chou, Steve C. Ludwig, Mohamad Bydon, Vedantam Rajshekhar, John M. Rhee, Andres Combalia, Carmen Vleggeert-Lankamp, Marjorie C. Wang, Adam S. Kanter, Langston T. Holly, Brandon D. Lawrence, Lucy Xiaolu Wang, Tom Mroz, Christopher I. Shaffrey, John G. Heller
Institutions: Lahey Hospital and Medical Center, Lahey Medical Center, University of Cincinnati, University of Miami, University of California, San Francisco, University of Wisconsin–Madison, Thomas Jefferson University, University Health Network, University of Toronto, Weill Cornell Medicine, Hospital for Special Surgery, Barrow Neurological Institute, Barrow Brain and Spine, University of Florida Health, University of Florida, Universidade de Caxias do Sul, Northwestern University, Northwestern Medicine, Loyola University Chicago, Rush University, Washington University in St. Louis, Cleveland Clinic Lerner College of Medicine, University of Maryland, Baltimore, University of Chicago, Christian Medical College, Vellore, Emory University, Universitat de Barcelona, Leiden University, Medical College of Wisconsin, Hoag Memorial Hospital Presbyterian, University of California, Los Angeles, University of Utah, University of Massachusetts Amherst, Max Planck Institute for Innovation and Competition, Duke University, Duke Medical Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7225912459
